Equities

Denali Therapeutics Inc

Denali Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)24.39
  • Today's Change0.17 / 0.70%
  • Shares traded586.80k
  • 1 Year change+34.75%
  • Beta1.3564
Data delayed at least 15 minutes, as of Nov 22 2024 20:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy6
Outperform8
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for Denali Therapeutics Inc have a median target of 40.00, with a high estimate of 90.00 and a low estimate of 28.00. The median estimate represents a 65.15% increase from the last price of 24.22.
High271.6%90.00
Med65.2%40.00
Low15.6%28.00

Earnings history & estimates in USD

On Nov 06, 2024, Denali Therapeutics Inc reported 3rd quarter 2024 losses of -0.63 per share. This result was in line with the consensus of the 16 analysts following the company and exceeded last year's 3rd quarter results by 12.50%.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate+1.99%
Denali Therapeutics Inc reported annual 2023 losses of -1.06 per share on Feb 27, 2024.
Average growth rate+25.22%
More ▼

Revenue history & estimates in USD

Denali Therapeutics Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 35.14m.
Average growth rate-25.00%
Denali Therapeutics Inc. had revenues for the full year 2023 of 330.53m. This was 204.74% above the prior year's results.
Average growth rate+350.06%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.